EA201200016A1 - Лечение приливов, вазомоторных симптомов и ночной потливости с помощью предшественников половых стероидов в комбинации с избирательными (селективными) модуляторами эстрогеновых рецепторов - Google Patents

Лечение приливов, вазомоторных симптомов и ночной потливости с помощью предшественников половых стероидов в комбинации с избирательными (селективными) модуляторами эстрогеновых рецепторов

Info

Publication number
EA201200016A1
EA201200016A1 EA201200016A EA201200016A EA201200016A1 EA 201200016 A1 EA201200016 A1 EA 201200016A1 EA 201200016 A EA201200016 A EA 201200016A EA 201200016 A EA201200016 A EA 201200016A EA 201200016 A1 EA201200016 A1 EA 201200016A1
Authority
EA
Eurasian Patent Office
Prior art keywords
estrogen receptors
vasomotor symptoms
selective
night
electoral
Prior art date
Application number
EA201200016A
Other languages
English (en)
Inventor
Фернанд Лабри
Original Assignee
Эндорешерш, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43306950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201200016(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эндорешерш, Инк. filed Critical Эндорешерш, Инк.
Publication of EA201200016A1 publication Critical patent/EA201200016A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Новые способы уменьшения частоты или устранения приливов, вазомоторных симптомов и ночной потливости и в то же время снижения риска возникновения рака молочной железы, матки или эндометрия, а также оказывающие положительный эффект путем торможения развития остеопороза, гиперхолестеринемии, гиерлипидемии, атеросклероза, гипертензии, устойчивости к инсулину, диабета 2-го типа, потери мышечной массы, ожирения, болезни Альцгеймера, ухудшения когнитивной способности, ухудшения памяти или вагинальной сухости у восприимчивых теплокровных животных, включая человека, которые включают введение дозы предшественника половых стероидов, предпочтительно дегидроэпиандростерона (DHEA), и антиэстрогена или избирательного модулятора эстрогеновых рецепторов, предпочтительно соединений, имеющих следующую общую структуру:
EA201200016A 2009-06-16 2010-06-16 Лечение приливов, вазомоторных симптомов и ночной потливости с помощью предшественников половых стероидов в комбинации с избирательными (селективными) модуляторами эстрогеновых рецепторов EA201200016A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18754909P 2009-06-16 2009-06-16
US12/791,174 US20100317635A1 (en) 2009-06-16 2010-06-01 Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
PCT/CA2010/000898 WO2010145010A1 (en) 2009-06-16 2010-06-16 Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators

Publications (1)

Publication Number Publication Date
EA201200016A1 true EA201200016A1 (ru) 2012-08-30

Family

ID=43306950

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200016A EA201200016A1 (ru) 2009-06-16 2010-06-16 Лечение приливов, вазомоторных симптомов и ночной потливости с помощью предшественников половых стероидов в комбинации с избирательными (селективными) модуляторами эстрогеновых рецепторов

Country Status (20)

Country Link
US (4) US20100317635A1 (ru)
EP (3) EP2442807A4 (ru)
JP (4) JP2012530074A (ru)
KR (10) KR20210048609A (ru)
CN (3) CN107468695A (ru)
AR (1) AR077119A1 (ru)
AU (1) AU2010262722A1 (ru)
BR (1) BRPI1011561A2 (ru)
CA (2) CA2893236A1 (ru)
CL (1) CL2011003172A1 (ru)
EA (1) EA201200016A1 (ru)
HK (1) HK1204550A1 (ru)
IL (2) IL216963A (ru)
MA (1) MA33434B1 (ru)
MX (1) MX338290B (ru)
NZ (1) NZ597583A (ru)
SG (3) SG10201705761YA (ru)
TW (1) TWI612044B (ru)
WO (1) WO2010145010A1 (ru)
ZA (1) ZA201109198B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
EA022551B1 (ru) 2010-06-10 2016-01-29 Серагон Фармасьютикалс, Инк. Модуляторы рецепторов эстрогена и их применение
ES2545337T3 (es) 2011-07-19 2015-09-10 Pantarhei Bioscience B.V. Comprimido que contiene dehidroepiandrosterona (DHEA)
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
CN104169266A (zh) 2011-12-16 2014-11-26 奥乐玛药物股份有限公司 新的苯并吡喃化合物、其组合物和用途
WO2013134311A1 (en) * 2012-03-07 2013-09-12 Ligand Pharmaceuticals, Inc. Steroid hormone and cholesterol pathways as one unified homestatic system
WO2014008159A1 (en) * 2012-07-03 2014-01-09 The University Of North Carolina At Chapel Hill Selective estrogen receptor degraders for treatment of tamoxifen resistant tumors
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-（对-（（z-4-氯-1,2-二苯基-1-丁烯基）苯氧基）乙醇的新型衍生物及其应用
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
EP3288534B1 (en) 2015-04-28 2020-09-23 Symrise AG Compositions comprising valerian extracts
SG11201803119XA (en) * 2015-10-27 2018-05-30 Sun Pharma Advanced Res Co Ltd Novel heterocyclic antiestrogens
WO2017162206A1 (zh) * 2016-03-25 2017-09-28 南京明德新药研发股份有限公司 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
JP7131773B2 (ja) * 2016-04-29 2022-09-06 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ホルモン受容体に関連する転写活性の標的尺度
CN109640958B (zh) 2016-05-20 2022-11-22 蔚蓝生物技术股份有限公司 包含选择性雌激素受体调节剂(serm)的阴道递送系统及其用途
TW201919594A (zh) * 2017-09-11 2019-06-01 美商艾陶莎基因有限公司 局部用組合物及治療方法
CN111328280A (zh) 2017-09-11 2020-06-23 阿托萨治疗学公司 制备和使用内昔芬的方法
WO2022203097A1 (ko) * 2021-03-24 2022-09-29 디어젠 주식회사 스트레스 과립의 조절제인 atxn2를 제어하여 tdp-43 단백질의 과잉생산을 억제하는 중추신경계질환의 예방 및 치료 조성물

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US60503A (en) 1866-12-18 Improvement in olaips foe gluing the tips on billiard cues
US3797444A (en) * 1971-04-19 1974-03-19 H Stubbs Towing guide
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
DE3333240A1 (de) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
CA1254514A (en) 1984-06-29 1989-05-23 Eugene Roberts Method for promoting nerve regeneration
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US5064654A (en) * 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5162037A (en) * 1988-04-01 1992-11-10 Whitson Laboratories, Inc. Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
ZA899112B (en) * 1988-12-01 1990-08-29 Schering Corp Compositions for transdermal delivery of estradiol
US5071644A (en) * 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US5707983A (en) 1990-08-29 1998-01-13 Humanetics Corporation Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes
US5292730A (en) 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
CN1100541C (zh) 1993-01-19 2003-02-05 恩多研究公司 脱氢表雄酮的治疗用途和传送系统
DE19681496T1 (de) 1995-07-11 1998-12-24 Henrik Carlsen Stirling-Maschine
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
CA2241462A1 (en) 1996-01-11 1997-07-17 Novo Nordisk A/S Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
CA2241623A1 (en) 1996-01-11 1997-07-17 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
WO1997032837A1 (fr) 1996-03-06 1997-09-12 Sumitomo Pharmaceuticals Co., Ltd. Derives estrogenes non steroidiens
ES2162198T3 (es) 1996-04-19 2001-12-16 American Home Prod Agentes estrogenos.
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US6150381A (en) 1998-06-09 2000-11-21 R.J. Reynolds Tobacco Company Methods of treating microbial infection and therapeutic formulations therefor
CN100377711C (zh) 1998-06-11 2008-04-02 内部研究股份有限公司 雄-5-烯-3β，17β-二醇的药物组合物及其用途
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EP1187618A1 (en) * 1999-06-04 2002-03-20 The General Hospital Corporation Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
ATE447947T1 (de) * 1999-07-06 2009-11-15 Endorech Inc Pharmazeutische zubereitungen zur behandlung von insulinresitenz
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
AU2991301A (en) * 2000-01-28 2001-08-07 Endorecherche Inc. Selective estrogen receptor modulators in combination with estrogens
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20050131005A1 (en) * 2002-04-30 2005-06-16 Jiabing Wang 4-azasteroid derivatives as androgen receptor modulators
MXPA05003446A (es) 2002-10-01 2005-07-05 Dainippon Pharmaceutical Co Compuestos espiro, composiciones medicinales que contienen los mismos, e intermediarios de los compuestos.
US20040121991A1 (en) 2002-12-20 2004-06-24 Araneo Barbara A. Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
US20090023917A1 (en) 2004-01-22 2009-01-22 Eli Lilly And Company Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms
WO2006009912A1 (en) * 2004-06-23 2006-01-26 Merck & Co., Inc. Estrogen receptor modulators
CN106038572A (zh) * 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
JP2009521408A (ja) * 2005-12-02 2009-06-04 サートリス ファーマシューティカルズ， インコーポレイテッド Ｃｄｃ２様キナーゼ（ＣＬＫ）のモジュレータおよびその使用方法
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
AU2012204083C1 (en) 2007-08-10 2015-02-05 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM

Also Published As

Publication number Publication date
MX2011013689A (es) 2012-04-02
CN102458404A (zh) 2012-05-16
MX338290B (es) 2016-04-07
US10342805B2 (en) 2019-07-09
CA2765446A1 (en) 2010-12-23
US20190269696A1 (en) 2019-09-05
KR20190090088A (ko) 2019-07-31
EP3178480A1 (en) 2017-06-14
US20130244989A1 (en) 2013-09-19
JP2014088442A (ja) 2014-05-15
KR20170078879A (ko) 2017-07-07
AU2010262722A1 (en) 2012-01-19
IL216963A0 (en) 2012-02-29
SG10201912379PA (en) 2020-02-27
CN104352504A (zh) 2015-02-18
TWI612044B (zh) 2018-01-21
IL216963A (en) 2017-12-31
CL2011003172A1 (es) 2012-05-25
AR077119A1 (es) 2011-08-03
CA2893236A1 (en) 2010-12-23
JP2018203785A (ja) 2018-12-27
ZA201109198B (en) 2012-08-29
SG10201705761YA (en) 2017-08-30
TW201100403A (en) 2011-01-01
KR20210048609A (ko) 2021-05-03
US11452731B2 (en) 2022-09-27
EP3682880A1 (en) 2020-07-22
WO2010145010A1 (en) 2010-12-23
IL248245A0 (en) 2016-11-30
CN107468695A (zh) 2017-12-15
KR20200108505A (ko) 2020-09-18
US20190269697A1 (en) 2019-09-05
US20100317635A1 (en) 2010-12-16
HK1204550A1 (en) 2015-11-27
EP2442807A1 (en) 2012-04-25
EP2442807A4 (en) 2013-06-26
JP2012530074A (ja) 2012-11-29
KR20190025752A (ko) 2019-03-11
KR20160072269A (ko) 2016-06-22
SG177497A1 (en) 2012-02-28
KR20170138584A (ko) 2017-12-15
JP2016029101A (ja) 2016-03-03
NZ597583A (en) 2014-10-31
KR20140070650A (ko) 2014-06-10
KR20150141195A (ko) 2015-12-17
MA33434B1 (fr) 2012-07-03
BRPI1011561A2 (pt) 2016-03-29
KR20120097470A (ko) 2012-09-04

Similar Documents

Publication Publication Date Title
EA201200016A1 (ru) Лечение приливов, вазомоторных симптомов и ночной потливости с помощью предшественников половых стероидов в комбинации с избирательными (селективными) модуляторами эстрогеновых рецепторов
AR068702A1 (es) Composiciones farmaceuticas
ME01122B (me) Jedinjenja i postupci za liječenje raka dojke
EA200801461A1 (ru) Агенты, связывающиеся с ядерными рецепторами
WO2004075832A2 (en) Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
MX363536B (es) Gel transdermico de progestina/estradiol.
AR018660A1 (es) Una composicion farmaceutica que comprende androst-5-en-3beta,17beta-diol o una prodroga del mismo; un kit y metodos terapeuticos que utilizan dicha composicion y un parche transdermico.
DOP2012000325A (es) Derivados de 6,7-dihidro-5h-benzo (7)anulenos, metodos para su preparacion, preparaciones farmaceuticas que los contienen y su uso para la preparacion de medicamentos
UA124241U (uk) Спосіб вибору пацієнта для подальшої терапії er-позитивного раку молочної залози
EP2582371A4 (en) METHODS FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF STROGEN-RELATED DISEASES
PA8771801A1 (es) Heterociclos sulfonilados utiles para la modulacion del receptor de progesterona
TR201200950T1 (tr) İlerlemiş meme kanseri tedavisi için 500 mg'lik bir dozajda fulvestrant.
EA201792524A1 (ru) Режим приема селективного модулятора рецептора прогестерона (sprm)
WO2009059806A3 (en) Preparation of 6-oxa-8alpha-steroid estrogen analogues - a new group of unnatural estrogens and their use in medicine
MA32477B1 (fr) Derives estratrienes comprenant des bioisosteres heterocycliques pour le cycle a phenolique
Farman et al. Extra-nuclear effects of estrogen on cortical bone in males require ERαAF-1
EA201000097A1 (ru) 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
Marsh et al. Sex-related differences in antidepressant response: when to adjust treatment
TH137260A (th) การรักษาอาการร้อนวูบวาบ, กลุ่มอาการจากการปรับขนาดหลอดเลือด, และอาการเหงื่อท่วมตัวในตอนกลางคืนด้วยสารตั้งต้นของสเตอรอยด์ทางเพศในการรวมกันกับสารปรับคุมเอสโตเจน รีเซปเตอร์อย่างเลือกจำเพาะ
TH137260B (th) การรักษาอาการร้อนวูบวาบ, กลุ่มอาการจากการปรับขนาดหลอดเลือด, และอาการเหงื่อท่วมตัวในตอนกลางคืนด้วยสารตั้งต้นของสเตอรอยด์ทางเพศในการ รวมกันกับสารปรับคุมเอสโตเจน รีเซปเตอร์อย่างเลือกจำเพาะ
BRPI0822415B8 (pt) conjugado de hidroxipolímero modificado, uso de conjugado de hidroxipolímero modificado, composição tendo efeito de matar célula de tumor, e, método para produzir o conjugado de hidroxipolímero modificado
AR104577A2 (es) Métodos para tratar o reducir la probabilidad de adquirir síntomas o enfermedades debidas a la menopausia
Christopher et al. Development of selective androgen receptor modulators (SARMs)
Kaplowitz et al. Precocious puberty: a guide for families
CN201499605U (zh) 卫生内裤